Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ALA-101 |
| Synonyms | |
| Therapy Description |
ALA-101 is an invariant natural killer T (iNKT) cell-based therapy targeting CD19, which may induce cytotoxicity against CD19-positive tumor cells (Blood (2022) 140 (Supplement 1): 12699-12700). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ALA-101 | ALA 101|ALA101 | CD19 Immune Cell Therapy 76 | ALA-101 is an invariant natural killer T (iNKT) cell-based therapy targeting CD19, which may induce cytotoxicity against CD19-positive tumor cells (Blood (2022) 140 (Supplement 1): 12699-12700). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07518329 | Phase I | ALA-101 | Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia. | Not yet recruiting | AUS | 0 |